Applying the Latest Evidence in Breast Cancer: Overcoming Endocrine Resistance in HR+/HER2- Breast Cancer
hosted byPrime Education, LLCApplying the Latest Evidence in Breast Cancer: Overcoming Endocrine Resistance in HR+/HER2- Breast Cancer is organized by Prime Education, LLC.
Release Date: August 4, 2023
Expiration Date: August 3, 2024
Description:
As patients reach later lines of therapy, treatment decision-making and sequencing can become more complex. In this third case in our clinical case challenge series, test your skills in individualizing treatment plans, treatment sequencing, and shared decision-making, for patients with HR+/HER2- breast cancer. Hear from a real-world patient, and see how you stack up against your peers as you consider treatment strategies and review expert narratives on the latest evidence.
This activity is delivered in partnership with CancerCare.
Learning Objectives:
• Differentiate novel therapies for HR+/HER2- breast cancer and triple-negative breast cancer (TNBC) based on mechanism of action, and clinical data for their safety and efficacy
• Design individualized treatment plans for patients with HR+/HER2- breast cancer based on recent evidence and patient-, disease-, and treatment-related factors
• Apply current evidence-based guidelines to treatment selection and sequencing to optimize patient outcomes
• Employ interprofessional strategies to monitor for and mitigate treatment-related adverse events
• Implement evidence-based approaches to engage patients in shared decision-making to support patient-centered care
Agenda:
• Advancing Evidence-Based, Guideline-Informed Approaches to Treatment Sequencing
• Differentiating Novel Therapies Based on Mechanism of Action and Patient-, Disease-, and Treatment-Related Factors
• Mitigating Adverse Events Associated with Novel Breast Cancer Treatments
• Improving Shared Decision-Making and Patient-Centered Care
